Size controlled nanomedicines for cancer therapy and imaging

Nanomedicine is potentially a new modality for cancer diagnosis and therapy. To advance the development of nanomedicines, it is crucial to address various formulation and development issues of nanomedicines and investigate and understand the correlation between the properties of nanomedicines and biological responses, to lay the foundation for the design of next-generation nanomedicines with optimal efficacy against cancers. In this seminar, I will discuss the development of size-controlled nanoconjugates and systematically evaluate their applications for cancer treatment and diagnosis. 

---

Jianjun Cheng earned his Ph.D. in materials science from the University of California, Santa Barbara in 2001. He was a senior scientist at Insert Therapeutics, Inc. from 2001 to 2004 and a postdoctoral fellow at MIT from 2004 to 2005. He joined the faculty of the University of Illinois at Urbana-Champaign in 2005 and is an associate professor of materials science and engineering and a Willett Faculty Scholar. Cheng is the co-inventor of 18 patents, seven of which are in active use in industry. He has co-authored more than 100 publications. He received a Prostate Cancer Foundation Competitive Award in 2007, a National Science Foundation CAREER Award in 2008, Teaching Excellence Awards at U of I for five times in 2008-2010, a Xerox Award for Outstanding Research at U of I in 2010, and an NIH Director’s New Innovator Award in 2010. He was appointed as an associate of the Center for Advanced Study in 2014. Cheng is also an associate editor of Biomaterials Science, Royal Society of Chemistry.